A Randomized Comparative study of efficacy and safety between %20 and %30 Hydrogen peroxide  in the Treatment  of Actinic keratosis

Nareen yousif  salih; Ali Mozan Dhahir  El-Ethawi

doi:10.56056/amj.2024.278

Authors

Nareen yousif salih Dermatology trainee, Sulaymaniyah dermatology teaching hospital, KRG, Iraq
Ali Mozan Dhahir El-Ethawi Professor of Dermatology, University of Sulaymaniyah College of medicine, Director of KBMS Sulaymaniyah

DOI:

https://doi.org/10.56056/amj.2024.278

Keywords:

Actinic keratosis, Hydrogen peroxide, Ultra violate light

Abstract

Background and objectives: Actinic keratosis is a premalignant skin lesion that presents clinically as a sand-like macule or papule on an erythematous base with a superficial scale due to atypical proliferation of keratinocytes and may progress to squamous cell carcinoma.The aim of this study was to compare the efficacy of hydrogen peroxide in treatment of actinic keratosis between two different concentrations (%20 and %30).

Methods: This is a randomized open label therapeutic trial of twenty patients with actinic keratosis has been enrolled, it was conducted from April 2022 to August 2022 at Sulaimaniah dermatology teaching center. Patients were divided to two treatment groups. Hydrogen peroxide %20 applied to the actinic lesions of group A, while group B applied 30% Hydrogen peroxide to the lesions. The solution was applied to the lesions in a circular motion for 20 seconds, for four rounds per session Patients were seen after a first session in two weeks. Maximum four sessions spaced out by 15 days are given until clearance.

Result: we conducted a randomized open label therapeutic trial. It was conducted from April 2022 to August 2022 at Sulaimaniah dermatology teaching center. Regarding response in Group A out of twenty actinic lesions, marked and moderate improvement was recorded in %40, %30 of the lesions respectively while the remaining lesions %30 of them showed slight improvement and no clinically clearance has been recorded. In comparsison, Group B out of twenty lesions %60 of them clinically cleared and slight improvement was recorded only in %20 of lesions. There were statistically significant differences between (20% & 30% Hydrogen peroxide ) in response (p-value=0.000). Regarding side effects; majority of patients (85%) in both groups had recorded burning sensation, irritation and transient erythema, while no scarring, pigmentation, atrophy has been recorded. There were no statically significant differences between two groups.

Conclusion: Hydrogen peroxide can be used as safe, alternative method to other modalities in treatment of actinic keratosis lesions, results would be better if higher concentration %30 used.

Downloads

Download data is not yet available.

References

Cramer P, Stockfleth E. Actinic keratosis: where do we stand and where is the future going to take us? Expert Opin Emerg Drugs. 2020 (1):49-58. doi: 10.1080/14728214.2020.1730810. Epub 2020. PMID: 32067498.

Youl PH, Janda M, Aitken JF, Del Mar CB, Whiteman DC, Baade PD. Body site distribution of skin cancer, premalignant and common benign pigmented lesions excised in general practice. Br J Dermatol 2011 ;165(1):35-43.

Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF. Department of Veteran Affairs Topical Tretinoin Chemoprevention Trial Group. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer. 2009 ;115(11):2523-30.

Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000; 42(1): S23-4.

Kennedy C, Willemze R, de Gruijl FR, Bavinck JN, Bajdik CD. The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer. J Invest Dermatol. 2003 ;120(6):1087-93.

Dianzani C, Conforti C, Giuffrida R, et al. Current therapies for actinic keratosis. Int J Dermatol. 2020 ;59(6):677-84.

Dinehart SM. The treatment of actinic keratoses. J Am. Acad Dermatol. 2000;42(1): S25-8.

Kao S, Kiss A, Efimova T, Friedman A. Ex vivo evaluation of cytotoxicity and melanocyte viability after A-101 hydrogen peroxide topical solution 40% or cryosurgery treatment in seborrheic keratosis lesions. J Am Acad Dermatol 2018 ;79(4):767-8.

Bigardi A, Milani M. Successful treatment of molluscum contagiosum skin infection with hydrogen peroxide 1% cream. J Eur Acad Dermatol Venereol. 2003;17(Suppl. 3):419.

Schianchi R, Nazzaro G, Veraldi S. Treatment of molluscum contagiosum with hydrogen peroxide. Clin Exp Dermatol. 2018 ;43(1):66-7.

DuBois JC, Jarratt M, Beger BB, Bradshaw M, Powala CV, Shanler SD. A-101, a Proprietary Topical Formulation of High-Concentration Hydrogen Peroxide Solution: A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Dose–Response Profile in Subjects with Seborrheic Keratosis of the Face. Dermatol Surg. 2018 ;44(3):330-40.

Murphy EC, Friedman AJ. Hydrogen peroxide and cutaneous biology: translational applications, benefits, and risks. J Am. Acad Dermatol. 2019 ;81(6):1379-86.

Röwert Huber J, Patel MJ, Forschner T, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification Br J Dermatol. 2007;156: 8-12.

Ali Sadeghinia, Delara Amir Dastmalchi, Nika Kianfar, Shayan Dasdar, Hamidreza Mahmoudi, Soheila Dabiran, Vahideh Lajevardi, Maryam Daneshpazhooh. Efficacy and safety of hydrogen peroxide topical solution in treating actinic keratosis: A randomized controlled trial. Dermatologic Therapy. 2021 Sep;34(5):e15097. doi: 10.1111/dth.15097/

Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2016 ,41(3):211-8. DOI: 10.1016/j.tibs.2015.12.001. PMID: 26778478; PMCID: PMC4783224.

Li Y, Wang J, Xiao W, Liu J, Zha X. Risk factors for actinic keratoses: A systematic review and meta-analysis. Indian J Dermatol. 2022 ;67(1):92.

Yaldiz M. Prevalence of actinic keratosis in patients attending the dermatology outpatient clinic. Medicine (Baltimore). 2019;98 (28): e16465.

Grandahl K, Olsen J, Friis KBE, Mortensen OS, Ibler KS. Photoaging and actinic keratosis in Danish outdoor and indoor workers. Photodermatol Photoimmunol Photomed.2019;35(4):201-7.

Acar A, Karaarslan I. Comparison of actinic keratosis and severity index with physician global assessment and total lesion count and the ability to predict skin cancer. Dermatol Pract Concept. 20221;12(1): e2022031.

Sadeghinia A, Dastmalchi DA, Kianfar N, et al. Efficacy and safety of hydrogen peroxide topical solution in treating actinic keratosis: A randomized controlled trial. Dermatol Ther. 2021; 34(5): e15097. doi: 10.1111/dth.15097. Epub 2021. PMID: 34392573.

Mundi N, Jordan K, Doyle P, Moore C. 33% hydrogen peroxide as a Neoadjuvant treatment in the surgical excision of non-melanoma skin cancers: a case series. J OTOLARYNGOL-HEAD N.2020 ;49:1-7.

Thai KE, Fergin P, Freeman M, et al. A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol. 2004 ;43(9):687-92. doi: 10.1111/j.1365-4632.2004.02056.x. PMID: 15357755.

Efudex [package insert]. Costa Mesa, CA: Valeant Pharmaceuticals North America; 2005.

Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol. 2000;42(1 Pt 2):25–28.

Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis. 2002 ,1;70(2 Suppl):30-6.

Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. J Am Acad Dermatol. 2002;47(4):571–577.

Neittaanmäki Perttu N, Karppinen TT, Grönroos M, Tani TT, Snellman E. Daylight photodynamic therapy for actinic keratoses: a randomized double blinded nonsponsored prospective study comparing 5 aminolaevulinic acid nanoemulsion (BF200) with methyl5 aminolaevulinate. Br J Dermatol 2014 ;171(5):1172-80.